Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohavens lead investigational drug from its Molecular Degrader of Extracellular...
United States New Haven Jennifer Porcelli Mike Beyer Regeneron Pharmaceuticals Inc Myostatin Program
Source: prnewswire.com